GS-6207 is currently in Phase II clinical trials as first-in-class HIV capsid inhibitor. This small molecule disrupts capsid functions and it is suitable to long-acting therapy due to its superb antiviral potency, low in vivo clearance and slow drug release kinetics. This talk will highlight some of the structure-based modeling and crystallography efforts that went into our  HIV capsid inhibitor discovery program, helping to  optimize the antiviral activities and to understand the MOA.

Targeting HIV capsid assembly by long-acting small molecule modulators

ACS Fall 2020 Virtual Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.